Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.

Hegde SS, Pulido-Rios MT, Luttmann MA, Foley JJ, Hunsberger GE, Steinfeld T, Lee T, Ji Y, Mammen MM, Jasper JR.

Pharmacol Res Perspect. 2018 Apr 30;6(3):e00400. doi: 10.1002/prp2.400. eCollection 2018 Jun.

2.

Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy.

Beattie DT, Pulido-Rios MT, Shen F, Ho M, Situ E, Tsuruda PR, Brassil P, Kleinschek M, Hegde S.

J Inflamm (Lond). 2017 Dec 6;14:28. doi: 10.1186/s12950-017-0175-2. eCollection 2017.

4.

Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.

Hegde SS, Hughes AD, Chen Y, Steinfeld T, Jasper JR, Lee TW, McNamara A, Martin WJ, Pulido-Rios MT, Mammen M.

J Pharmacol Exp Ther. 2014 Oct;351(1):190-9. doi: 10.1124/jpet.114.216861. Epub 2014 Aug 6.

PMID:
25100753
5.

In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.

Pulido-Rios MT, McNamara A, Obedencio GP, Ji Y, Jaw-Tsai S, Martin WJ, Hegde SS.

J Pharmacol Exp Ther. 2013 Aug;346(2):241-50. doi: 10.1124/jpet.113.203554. Epub 2013 May 17.

PMID:
23685545
6.

Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and β(2)-adrenoceptor agonist (MABA).

McNamara A, Steinfeld T, Pulido-Rios MT, Stangeland E, Hegde SS, Mammen M, Martin WJ.

Pulm Pharmacol Ther. 2012 Oct;25(5):357-63. doi: 10.1016/j.pupt.2012.06.007. Epub 2012 Jul 2.

PMID:
22766316
7.

Application of the classical Einthoven model of bronchoconstriction to the study of inhaled bronchodilators in rodents.

McNamara A, Pulido-Rios MT, Hegde SS, Martin WJ.

J Pharmacol Toxicol Methods. 2011 Jan-Feb;63(1):89-95. doi: 10.1016/j.vascn.2010.05.016. Epub 2010 Jun 8.

PMID:
20594937
8.

In vitro isolated tissue functional muscarinic receptor assays.

Pulido-Rios MT, Steinfeld T, Armstrong S, Watson N, Choppin A, Eglen R, Hegde SS.

Curr Protoc Pharmacol. 2010 Mar;Chapter 4:Unit 4.15. doi: 10.1002/0471141755.ph0415s48.

PMID:
22294371
9.

In vivo pharmacodynamic assays for M2 and M3 muscarinic receptors.

Armstrong S, Steinfeld T, Pulido-Rios MT, Hegde SS.

Curr Protoc Pharmacol. 2010 Mar;Chapter 12:Unit 12.13. doi: 10.1002/0471141755.ph1213s48.

PMID:
22294364
10.

In vitro muscarinic receptor radioligand-binding assays.

Steinfeld T, Pulido-Rios MT, Armstrong S, Hegde SS.

Curr Protoc Pharmacol. 2010 Mar;Chapter 1:Unit 1.33. doi: 10.1002/0471141755.ph0133s48.

PMID:
22294363
11.

5-Hydroxytryptamine receptor assays.

Figueroa KW, Martin GR, Pulido-Rios MT.

Curr Protoc Pharmacol. 2009 Sep;Chapter 4:Unit4.19. doi: 10.1002/0471141755.ph0419s46.

PMID:
22294394
12.

Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.

McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, Wilson RD, Jasper JR, Mammen M, Hegde SS.

Eur J Pharmacol. 2009 Mar 1;605(1-3):145-52. doi: 10.1016/j.ejphar.2008.12.043. Epub 2009 Jan 10.

PMID:
19168050
14.

Comparison of 5-HT4 receptors in guinea-pig colon and rat oesophagus: effects of novel agonists and antagonists.

Leung E, Pulido-Rios MT, Bonhaus DW, Pekins LA, Zeitung KD, Hsu SA, Clark RD, Wong EH, Eglen RM.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Jul;354(2):145-56.

PMID:
8857591
15.

Supplemental Content

Loading ...
Support Center